Thrombosis Update · 2024 · 17 citations · 76 references
MedicineHematologyImmunologyCell TherapyImmunotherapyStem Cell TransplantationCoagulation AbnormalitiesThrombosisThrombosis ManagementThrombotic DisordersTransplant ComplicationsVenous ThromboembolismEndothelial Contribution To ThrombosisEndothelial Injury ResponseHematopoietic Stem Cell Transplantation ImmunotherapyThrombosis After Vascular InjuryThrombosis MechanismsThrombotic Complications After TransplantationVascular Endothelial Dysfunction
Hematopoietic stem cell transplantation (HSCT) and chimeric antigen receptor-T (CAR-T) immunotherapy are widely used for the management of hematological malignancies. HSCT can be complicated by endothelial injury syndromes, such as HSCT-thrombotic microangiopathy (HSCT-TMA) and sinusoidal obstructive syndrome/ veno-occlusive disease (SOS/VOD), which are life-threatening. Moreover, venous thromboembolic events (VTEs) are common in HSCT recipients due to endothelial injury, use of central venous catheters, prolonged hospitalization, and the development of a procoagulant state. VTEs have also been reported post-CAR-T infusion. The management of thrombotic events in these patients is challenging, due to the high risk of bleeding that is present. CAR-T immunotherapy might be followed by toxicities, such as cytokine release syndrome (CRS) and immune effector cell-associated neuro-toxicity syndrome (ICANS). Endothelial dysfunction is implicated in the pathogenesis of these syndromes. Early recognition and management of the above complications are crucial for better outcomes for our patients.
76
VENOOCCLUSIVE DISEASE OF THE LIVER FOLLOWING BONE MARROW TRANSPLANTATION
Richard J. Jones, KAMTHORN S. K. LEE, William E. Beschorner et al. · Transplantation · 1987 · 914 citations
Medicine, Hematology, Surgery +14
Mohamad Mohty, Florent Malard, Michaël Abécassis et al. · Bone Marrow Transplantation · 2016 · 529 citations · Full text